Powering a New Level of Independence

A Powered Lower Limb Orthosis that delivers unprecedented usability and efficacy

Indego® is a powered lower limb orthotic device that enables clinicians to conduct over-ground, task specific gait training and offers people with impaired mobility a new level of independence. Designed for personal use, but currently being researched in clinical settings, Indego offers a range of features that make it unique as a therapy tool for a variety of impairments.
A Range of Features Make Indego the Ideal Personal Device

COMBINING A LIGHTWEIGHT, MODULAR DESIGN WITH INTUITIVE CONTROLS, INDEGO OFFERS UNPARALLELED USABILITY

Indego boasts features that set it apart in form and function not only for the user, but also for clinicians. These unique features provide people with spinal cord injury, or weakness due to other neurological impairments,* the ability to stand, walk, sit and gait train in new ways.

RAPID SET-UP

Indego can be put on and taken off quickly because of a modular design, no-look connections and turn-to-fit strapping allowing for maximized therapy time.

SMART SIGNAL AND CONTROLS

Intuitive postural cues, vibratory feedback, LED indicators and a mobile control app work together to optimize the learning and teaching experience.

LIGHTWEIGHT, SLIM, MODULAR DESIGN

At just 26lbs (12kg), Indego is light, easy to handle for the clinician and user, and allows for rapid set-up, removal and transport. Indego can also be worn in a wheelchair.

EXTENDED BATTERY LIFE

Indego has a long-lasting, quick-change, rechargeable battery that allows for continuous use throughout the day.

NATURAL HUMAN MOVEMENT

Mimicking natural movement through postural cues, users lean forward to stand or walk and lean backward to stop or sit.

MANAGE PARAMETERS AND RECORD PROGRESS

Indego’s software app allows you to control gait training parameters such as stride length and pace, and record performance data for each patient.

*Pending Future Regulatory Approvals
From the Clinic to Home

Indego enables people with impaired mobility to stand and walk, and holds great promise as a therapy tool and as a personal device.

Indego is currently being tested in clinical settings where Parker has partnered with some of the world’s leading rehabilitation centers to establish a body of clinical evidence that demonstrates the benefits of the device for therapy and personal use. Parker aims for Indego to be the first exoskeleton approved by the FDA for use in the U.S. and is pursuing CE marking in Europe. Commercial launch of Indego is targeted for early 2015 in Europe and 2016 in the U.S.

Indego is uniquely positioned to revolutionize modern gait training and establish a new standard of care for rehabilitation of people with mobility impairments. Indego can provide self-initiated, task-specific, intense gait training on a variety of surfaces and maximizes patient engagement. With its intuitive operation and slim design, Indego training sessions can be conducted with the assistance of just one clinician.

The unique features of Indego allow for a seamless transition from use in the clinical setting to rehabilitation at home or in the community, and ultimately for use as a personal mobility device. Indego comes in three sizes (small, medium and large) with interchangeable sections, making it suitable for a range of users.

CLINICAL PARTNERS

Shepherd Center
Kessler Foundation
Rehabilitation Institute of Chicago
Craig Hospital
Disclaimer: Parker Hannifin Corporation is currently engaged with Shepherd Center in the development of the technology described herein. This technology has not been submitted for FDA approval and is not currently available for sale. Continued development and testing of this device is anticipated to lead to FDA approval to market and sell this device for clinical rehabilitation and also for personal mobility, at which time indications for use and benefits of use will be announced. The information provided herein is indicative of the current research findings from clinical experiments performed with this device and should not be considered to provide approved indications for use or benefits of use.